Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + Gemcitabine + Oxaliplatin in R/R DLBCL
NCT06624085Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Primary endpoints: Incidence of Adverse Events at 3 years and Complete Response Rate at 3 years. Started Apr 2025; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06624085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624085.